Are peptides legal in Montana?

Peptides are legally gray in Montana: the state has no statute or Board of Pharmacy rule that specifically names peptides, 'research chemicals,' or research-use-only compounds, so their status runs through the same general pharmacy and FDA compounding framework that applies to any other unapproved drug ingredient. Montana licenses and inspects compounding pharmacies under its Pharmacy Practice Act and Board of Pharmacy administrative rules, and those pharmacies are in turn bound by FDA's 503A/503B bulk-drug-substance rules, which is why peptides like BPC-157 and compounded semaglutide/tirzepatide have been restricted or removed from compounding bulk lists at the federal level. Separately, Montana passed its own first-in-the-nation 'Right to Try' expansion, Senate Bill 535 (2025), creating a state licensing pathway for 'Experimental Treatment Centers' to offer Phase-1-tested investigational drugs and biologics, which could in theory reach peptide-based products, but this is a general experimental-treatment framework rather than a peptide-specific law.

• Montana's Board of Pharmacy administrative rules (ARM Title 24, chapter 174) define compounding, institutional pharmacy, and compounded sterile preparations in general terms but contain no distinct category or special rule for peptides or 'research chemicals.' ^[1]
• Any compounded peptide dispensed in Montana must go through a Montana-licensed pharmacy operating under the state's general compounding rules, and that pharmacy must separately satisfy the federal FDA Section 503A patient-specific-prescription exemption to avoid being treated as an unapproved new drug. ^[2]
• Montana-licensed 503A compounding pharmacies, including facilities in Missoula, MT, are subject to routine FDA inspection and can receive FDA Form 483 observations, untitled letters, or warning letters for compounding violations under this federal framework. ^[3]
• A person cannot legally buy peptides for human use in Montana without a prescription filled through a licensed compounding pharmacy operating under the FDA's 503A patient-specific exemption; peptides sold online labeled 'for research use only, not for human consumption' fall outside this legal pathway. ^[2]
• Montana enacted Senate Bill 535 in 2025, a first-in-the-nation expansion of its Right to Try Act that lets the Department of Public Health & Human Services license 'Experimental Treatment Centers' to provide investigational drugs, biologics, or devices that have completed only Phase 1 safety trials, with informed consent required. ^[4]
• Compounded semaglutide and tirzepatide, the active ingredients behind many GLP-1 weight-loss peptide products, lost their shortage-based compounding eligibility and were targeted for exclusion from FDA's bulk drug substance lists once the national shortages ended in 2024-2025, narrowing the legal compounding pathway for these drugs nationwide, including in Montana. ^[8]
• BPC-157 has been reviewed by FDA's Pharmacy Compounding Advisory Committee as a candidate bulk drug substance and is listed by the World Anti-Doping Agency as a prohibited non-approved substance, reflecting its unapproved, non-prescription-drug status that applies uniformly in Montana as elsewhere in the US. ^[7]
• No Montana-specific criminal statute or enforcement bulletin targeting peptide research chemicals was found during this research; documented enforcement in Montana has instead occurred through the general federal compounding-pharmacy oversight process (FDA inspections, 483s, and warning letters issued to licensed Montana pharmacies). (No reliable source found for this point — flagged as unverified rather than stated as fact.)

• Montana Board of Pharmacy Administrative Rules (ARM ch. 174, as of 06/30/2021) — Montana Board of Pharmacy administrative rules (ARM Title 24, chapter 174) define and govern drug compounding, institutional pharmacy, and compounded sterile preparations generally, with no distinct category for peptides or research chemicals. (retrieved 2026-10-02)
• FDA - Prescription Requirement Under Section 503A of the Federal Food, Drug, and Cosmetic Act — FDA guidance on Section 503A of the FD&C Act explains that compounded human drug products are exempt from new-drug and labeling requirements only when compounded by a licensed pharmacist/physician pursuant to a valid patient-specific prescription. (retrieved 2026-10-02)
• FDA - Compounding: Inspections, Recalls, and Other Actions — FDA's compounding inspections/enforcement tracking page lists multiple Montana 503A compounding pharmacies, including OSRX, Inc. in Missoula, MT, which received a Form 483 in 2021 and prior untitled/warning letters. (retrieved 2026-10-02)
• Montana 69th Legislature (2025) - SB 535 Enrolled Bill — Montana Senate Bill 535 (2025), the enrolled bill text, creates licensing for 'Experimental Treatment Centers' and amends the state's Right to Try Act to allow access to investigational drugs/biologics that have completed Phase 1 trials. (retrieved 2026-10-02)
• montanabio.org - SB535: Right to Try Montana — Plain-language summary confirming SB 535 establishes a DPHHS licensing pathway for Experimental Treatment Centers offering Phase-1-tested investigational drugs/biologics/devices with required informed consent, effective May 13, 2025. (retrieved 2026-10-02)
• American Med Spa Association - Compounded GLP-1 FAQ — Small-scale (503A) compounders had to stop producing compounded tirzepatide immediately and larger 503B outsourcing facilities had a wind-down deadline, as part of the national rollback of compounded GLP-1 availability. (retrieved 2026-10-02)
• USADA - BPC-157: Experimental Peptide Creates Risk for Athletes — BPC-157 has been reviewed by FDA's Pharmacy Compounding Advisory Committee as a bulk drug substance and is listed on the WADA Prohibited List in the non-approved substances category. (retrieved 2026-10-02)
• Pharmacy Times - FDA Moves to Permanently Close the Door on Compounded GLP-1s — FDA proposed to formally exclude semaglutide, tirzepatide, and liraglutide from the 503B outsourcing facility bulk drug substances list, closing off the regulatory mechanism that allowed large-scale compounding of these GLP-1 peptide drugs. (retrieved 2026-10-02)
• FDA Warning Letter - Montana Compounding Pharmacy PC (05/09/2018) — FDA issued a warning letter to a Montana compounding pharmacy explaining Section 503A's conditions for exemption from CGMP and new-drug approval requirements, illustrating that Montana compounders are governed by and can be enforced against under federal 503A compounding law. (retrieved 2026-10-02)

Last researched: 2026-10-02